SOPHiA GENETICS Unveils AI Digital Twins for Smarter Oncology Decisions

BOSTON and ROLLE, Switzerland, Oct. 16, 2025 – SOPHiA GENETICS (Nasdaq: SOPH), a prominent player in the burgeoning field of AI-driven precision medicine, has unveiled its latest innovation: SOPHiA DDM™ Digital Twins. This cutting-edge research technology promises to revolutionize oncology by generating dynamic, virtual representations of individual patients. The goal is to simulate potential treatment outcomes, thereby empowering oncologists to make more informed and effective therapeutic decisions.

SOPHiA DDM™ Digital Twins leverages a patient’s comprehensive data profile, encompassing clinical history, biological markers, imaging results, and genomic information, to construct a sophisticated computational model replicating the patient and their specific disease. By creating this “Digital Twin,” oncologists gain the ability to simulate various treatment scenarios, predict disease progression, and anticipate survival outcomes in real-time. This allows for thorough exploration of therapeutic strategies in a virtual environment before any decisions are made affecting patient care.

“Digital twin technology allows for the integrated visualization of diverse oncologic data, pinpointing previously unseen correlations across modalities. By simulating disease paths and responses to treatments in a virtual space, Digital Twins create a framework for *in silico* experimentation, helping to anticipate and individualize clinical decisions,” notes Dr. Pierre Heudel, a Medical Oncologist at Centre Léon Bérard. This highlights the potential of Digital Twins to move beyond retrospective analysis and into predictive, personalized medicine.

Dr. Clara Montagut, Head of Gastrointestinal Cancer at Hospital del Mar, emphasizes the potential transformative impact on patient care, stating, “This breakthrough represents a major leap forward in enabling clinicians to make better decisions for complex cancers. The ability to simulate possible outcomes before treatment has the potential to reshape how we provide care in the future.”

The power of Digital Twins stems from the collective insights of the SOPHiA GENETICS community, combined with a multi-layered, longitudinal dataset that accurately simulates potential therapy responses. The tool provides clinicians with data-derived insights drawn from a wide network of patient cases worldwide, breaking down conventional institutional and geographical hindrances. This democratization of global intelligence further helps improve clinical decision-making. This network effect and the power of aggregated, anonymized data are critical differentiators in the precision medicine space.

“Building on the foundation of preclinical and clinical research, digital-twin technology opens up new possibilities for improving the diagnosis and management of intricate diseases like cancer. SOPHiA DDM™ Digital Twins offers clinicians and researchers a robust, data-driven method for hypothesis testing and advancing the implementation of precision medicine on a wider scale,” comments Dr. Ernest Nadal, Director of Research and Innovation at the Catalan Institute of Oncology.

According to Dr. Mariano Provencio Pulla, Head of the Medical Oncology Department at Puerta de Hierro University Hospital, “The Digital Twins concept developed by SOPHiA GENETICS is a genuine breakthrough in oncology. This approach is vital for leveraging the significant clinical advancements of recent years, particularly in pre-surgical immunotherapy for non-small cell lung cancer patients eligible for surgery. I believe it’s the future of data-driven medicine.”

Fueled by advanced artificial intelligence, SOPHiA DDM™ Digital Twins continuously learns and refines its accuracy as new data are incorporated. This AI-driven evolution strengthens both research capabilities and predictive power over time. The platform also generates synthetic data mirroring real-world disease patterns, allowing researchers to explore new avenues of treatment and model potential consequences before starting any treatment strategy.

“Because cancer is constantly changing, static observations are insufficient,” asserts Jurgi Camblong, Ph.D., Co-Founder & CEO of SOPHiA GENETICS. “With SOPHiA DDM™ Digital Twins, we can build sophisticated AI models based on our wide patient network, accelerating research, refining clinical decisions, and transforming current knowledge into future breakthroughs. This embodies our goal to establish data-driven medicine as the standard of care worldwide.”

SOPHiA DDM™ Digital Twins introduces key features with the potential to redefine precision oncology:

• Personalized Treatment Insights: Enables oncologists to precisely match patients with the most effective treatment strategies based on simulated results, and facilitates discovery of relevant clinical trials.
• Toxicity and Cost Avoidance: Offers insights helping physicians lower patient exposure to treatments that may not work, which then prevents needless side effects and costs.
• Global Knowledge, Local Impact: Employs one of the largest anonymized datasets of cancer cases to enable better clinical decisions for oncologists.

This marks a new chapter in precision oncology, where technology empowers physicians to transcend retrospective data and adopt AI-guided decision support, tailored specifically to each patient. The Digital Twins system is launching on the SOPHiA DDM^TM Platform for lung cancer, with plans to expand to other cancer types in the months ahead.

SOPHiA GENETICS is poised to capitalize on the growing demand for personalized cancer treatment. The Digital Twins platform is a significant advancement with the potential to disrupt current standard practices and influence patient outcomes for the better. Whether the company can successfully commercialize the platform and secure a substantial market share remains to be seen, but early signals point to a potentially transformative impact on the oncology field.

About SOPHiA GENETICS

SOPHiA GENETICS (Nasdaq: SOPH) operates as a cloud-native healthcare technology enterprise focused on advancing access to data-driven medicine. By using AI, the company seeks to provide exceptional care to cancer and rare disorder patients globally. SOPHiA GENETICS is known for the SOPHiA DDM™ Platform, which analyzes comprehensive genomic and multimodal data, to generate real-time, actionable insights for a broad global network of hospital, laboratory and biopharma institutions.

SOPHiA DDM™ Digital Twins is for Research Use Only and not for use in diagnostic procedures unless specified otherwise. The information in this press release is about products that may or may not be available in different countries and, if applicable, may or may not have received approval or market clearance by a governmental regulatory body for different indications for use.

SOPHiA GENETICS Forward-Looking Statements:

This press release contains statements that constitute forward-looking statements. All statements other than statements of historical facts contained in this press release, including statements regarding our future results of operations and financial position, business strategy, products, and technology, as well as plans and objectives of management for future operations, are forward-looking statements. Forward-looking statements are based on our management’s beliefs and assumptions and on information currently available to our management. Such statements are subject to risks and uncertainties, and actual results may differ materially from those expressed or implied in the forward-looking statements due to various factors, including those described in our filings with the U.S. Securities and Exchange Commission. No assurance can be given that such future results will be achieved. Such forward-looking statements contained in this press release speak only as of the date hereof. We expressly disclaim any obligation or undertaking to update these forward-looking statements contained in this press release to reflect any change in our expectations or any change in events, conditions, or circumstances on which such statements are based, unless required to do so by applicable law. No representations or warranties (expressed or implied) are made about the accuracy of any such forward-looking statements.